Lantern Pharma Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Lantern Pharma Inc. (LTRN) reported Increase (Decrease) in Prepaid Expense and Other Assets of $412.71 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-14
- Lantern Pharma Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $363.21K, a 85.78% increase year-over-year.
- Lantern Pharma Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $49.51K.
- Lantern Pharma Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$415.00K.
- Lantern Pharma Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$201.22K.
- Lantern Pharma Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$554.10K.
- Lantern Pharma Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$778.30K.
- Lantern Pharma Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$941.44K, a 191.06% decline from fiscal 2022.
- Lantern Pharma Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $1.03M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $363.21K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $412.71K 10-Q · filed 2026-08-14 | -$2.29K derived: sum of 3 quarters · filed 2026-08-14 | -$203.51K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $49.51K 10-Q · filed 2026-05-15 | -$365.50K derived: sum of 2 quarters · filed 2026-05-15 | -$566.72K derived: sum of 3 quarters · filed 2026-05-15 | -$371.21K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$415.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$616.23K derived: sum of 2 quarters · filed 2026-03-30 | -$420.72K derived: sum of 3 quarters · filed 2026-08-14 | -$554.10K 10-K · filed 2026-03-30 |
| 2025-09-30 | -$201.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$5.71K derived: sum of 2 quarters · filed 2026-08-14 | -$139.09K 10-Q · filed 2025-11-12 | -$762.11K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $195.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $62.13K 10-Q · filed 2026-08-14 | -$560.89K derived: sum of 3 quarters · filed 2026-08-14 | -$729.10K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$133.38K 10-Q · filed 2026-05-15 | -$756.40K derived: sum of 2 quarters · filed 2026-05-15 | -$924.61K derived: sum of 3 quarters · filed 2026-05-15 | -$10.66K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$623.02K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$791.24K derived: sum of 2 quarters · filed 2026-03-30 | $122.71K derived: sum of 3 quarters · filed 2026-03-30 | -$778.30K 10-K · filed 2026-03-30 |
| 2024-09-30 | -$168.21K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $745.74K derived: sum of 2 quarters · filed 2025-11-12 | -$155.28K 10-Q · filed 2025-11-12 | -$654.65K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $913.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $12.93K 10-Q · filed 2025-08-13 | -$486.43K derived: sum of 3 quarters · filed 2025-08-13 | -$513.39K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$901.02K 10-Q · filed 2025-05-15 | -$1.40M derived: sum of 2 quarters · filed 2025-05-15 | -$1.43M derived: sum of 3 quarters · filed 2025-05-15 | -$1.96M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$499.36K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$526.33K derived: sum of 2 quarters · filed 2025-03-27 | -$1.06M derived: sum of 3 quarters · filed 2025-03-27 | -$941.44K 10-K · filed 2025-03-27 |
| 2023-09-30 | -$26.96K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$559.71K derived: sum of 2 quarters · filed 2024-11-07 | -$442.08K 10-Q · filed 2024-11-07 | -$1.17M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$532.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$415.11K 10-Q · filed 2024-08-08 | -$1.14M derived: sum of 3 quarters · filed 2024-08-08 | -$943.38K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $117.64K 10-Q · filed 2024-05-09 | -$608.39K derived: sum of 2 quarters · filed 2024-05-09 | -$410.63K derived: sum of 3 quarters · filed 2024-05-09 | $711.29K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$726.03K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$528.27K derived: sum of 2 quarters · filed 2024-03-18 | $593.65K derived: sum of 3 quarters · filed 2024-03-18 | $1.03M 10-K · filed 2024-03-18 |
| 2022-09-30 | $197.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.32M derived: sum of 2 quarters · filed 2023-11-08 | $1.76M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.56M 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $440.17K 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |